Serum Levels of the C-terminal Fragment of Fibroblast Growth Factor 23 (C-FGF23) and Hepcidin in Patients with Hemodialysis Undergoing Treatment with a Proline Hydroxylase Domain (PHD) Inhibitor
Article Sidebar
Main Article Content
Abstract
Background: We previously reported, for the first time, serum levels of the C-terminal fragment of fibroblast growth factor 23 (C-FGF23) in patients undergoing hemodialysis (HD). Most HD patients have undergone treatment with either recombinant erythropoietin (r-EPO) or hypoxia-inducible factor (HIF) proline hydroxylase domain (PHD) inhibitor, both of which stimulate FGF23 production and cleavage.
Methods: This cross-sectional observational study involved analyzing measuring FGF-related parameters and comparing results for subgroups of patients who received either r-EPO and or a PHD inhibitor.
Results: No significant difference was observed for iron-related parameters or serum hepcidin levels in both subgroups of patients. Significant differences were found for certain FGF-23-related parameters.
Conclusion: Both FGF23 production and cleavage were stimulated more in patients treated with the PHD inhibitor than in patients treated with r-EPO.
Article Details
Copyright (c) 2024 Motomiya Y, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The Journal of Clinical Nephrology is committed in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. In order to use the Open Access paradigm to the maximum extent in true terms as free of charge online access along with usage right, we grant usage rights through the use of specific Creative Commons license.
License: Copyright © 2017 - 2025 | 
Open Access by Journal of Clinical Nephrology is licensed under a Creative Commons Attribution 4.0 International License. Based on a work at Heighten Science Publications Inc.
With this license, the authors are allowed that after publishing with the journal, they can share their research by posting a free draft copy of their article to any repository or website.
Compliance 'CC BY' license helps in:
| Permission to read and download | ✓ |
| Permission to display in a repository | ✓ |
| Permission to translate | ✓ |
| Commercial uses of manuscript | ✓ |
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
Rankin ER, Biju MP, Liu Q, Unger TL, Rha J, Johnson RS, et al. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest. 2007;117:1068-1077. Available from: https://doi.org/10.1172/jci30117
Zhang Q, Doucel M, Tomlinson RE, Han X, Quarles LD, Collins MT, et al. The hypoxia-inducible factor-1α activates ectopic production of fibroblast growth factor 23 in tumor-induced osteomalacia. Bone Res. 2016;4:16011. Available from: https://doi.org/10.1038/boneres.2016.11
MacMahon S, Gorondin F, McDonald PP, Richard DE, Dubois CM. Hypoxia-enhanced expression of the proprotein convertase furin is mediated by hypoxia-inducible factor-1. J Biol Chem. 2005;280:6561-6569. Available from: https://doi.org/10.1074/jbc.m413248200
Daryadel A, Bettoni C, Haider T, Siva PI, Schnitzbauer U, Pastor-Arroyo EM, et al. Erythropoietin stimulates fibroblast growth factor 23 (FGF23) in mice and men. Pflugers Arch. 2018;470:1569-82. Available from: https://doi.org/10.1007/s00424-018-2171-7
Toro I, Barrientos V, Leon P. Erythropoietin induces bone marrow and plasma fibroblast growth factor 23 during acute kidney injury. Kidney Int. 2017;93:1131-1141. Available from: https://doi.org/10.1016/j.kint.2017.11.018
Kautz M, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46:678-684. Available from: https://doi.org/10.1038/ng.2996
Courbon G, Thomas JJ, Martinez-Calle M, Wang X, Spinde J, Drasek JV, Hunt-Tobey B, Mehta R, Isakova T, Chang W, Ceemers JWM, Ji P, Martin A, David V. Bone-derived C-terminal FGF23 cleaved peptides increase iron availability in acute inflammation. Blood. 2023;142:106-118. Available from: https://doi.org/10.1182/blood.2022018475
Tanaka K, Higashimoto Y, Tomizawa M, Motomiya Y, Kaneko Y. Circulating levels of fibroblast growth factor 23 selective for C-terminal (FGF23-CT) in hemodialysis patients. J Clin Nephrol. 2023;7:085-91. Available from: https://doi.org/10.29328/journal.jcn.1001115
Motomiya Y, Kaneko Y, Higashimoto Y. Clinical usefulness of the serum-soluble transferrin receptor in iron dysregulation associated with long-term hemodialysis. Int J Clin Case Rep Rev. 2024;17(2):[Epub ahead of print]. Available from: https://www.auctoresonline.org/uploads/articles/1714397129IJCCR-24-RA-430-Galley_Proof.pdf
Coe LM, Madathil SV, Casu C, Lanske B, Rivella S, Sitara D. FGF23 is a negative regulator of prenatal and postnatal erythropoiesis. J Biol Chem. 2014;289:9795-9810. Available from: https://doi.org/10.1074/jbc.m113.527150
Goetz R, Nakada Y, Hu MC, Mohammadi M. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci U S A. 2009;107:407-412. Available from: https://doi.org/10.1073/pnas.0902006107
Agoro R, Montagna A, Goetz R, Allegbe O, Singh G, Coe LM, et al. Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia. FASEB J. 2018;32:3752-3764. Available from: https://doi.org/10.1096/fj.201700667r
Winder A, Lefkowitz R, Ghoti H, Leiba M, Ganz T, Nemeth E, et al. Urinary hepcidin excretion in patients with myelodysplastic syndrome and myelofibrosis. Br J Haematol. 2008;142:669-671. Available from: https://doi.org/10.1111/j.1365-2141.2008.07225.x
Nemeth E, Rivera S, Gabayan Y, Keller C, Taudorf S, Pederson BK, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113:1271-1276. Available from: https://doi.org/10.1172/jci20945
Ganz T, Nemeth E. Iron balance and the role of hepcidin in chronic kidney disease. Semin Nephrol. 2016;36:87-93. Available from: https://doi.org/10.1016/j.semnephrol.2016.02.001
Singh S, Grabner A, Yanucil C, Schramm K, Czaya B, Krick S, et al. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int. 2016;90:985-996. Available from: https://doi.org/10.1016/j.kint.2016.05.019
Flamme I, Ellinghaus P, Urrego D, Krüger T. FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase. PLoS One. 2017;12. Available from: https://doi.org/10.1371/journal.pone.0186979
van Vuren AJ, Gaillard CJM, Eisenga MF, van Wijk R, van Beers E. The EPO-FGF23 signaling pathway in erythroid progenitor cells: opening a new area of research. Front Physiol. 2019;10:304. Available from: https://doi.org/10.3389/fphys.2019.00304
Las Rivas M, Daniel EJP, Narimatsu Y, Companon I, Kato K, Hemosilla P, et al. Molecular basis for fibroblast growth factor 23 O-glycosylation by GalNAc-T3. Nat Chem Biol. 2020;16:351-360. Available from: https://doi.org/10.1038/s41589-019-0444-x
Hanudel MR, Eisenga M, Rappaport M, Chua K, Qiao B, Jung G, et al. Effects of erythropoietin on fibroblast growth factor 23 in mice and humans. Nephrol Dial Transplant. 2019;34:2057-2065. Available from: https://doi.org/10.1093/ndt/gfy189